Overview of Dermapharm's Q4 Results#
Dermapharm Holding SE, a German pharmaceutical company, released its preliminary results for the fourth quarter and the full year 2025. The figures were at the lower end of the company's guidance, indicating some challenges in meeting expectations.
Sales Performance#
In the fourth quarter, Dermapharm reported sales of €296 million, which is a 2% increase compared to the same period last year. However, this figure was 6% below the consensus estimate of €313 million, highlighting a shortfall in sales expectations.
Adjusted EBITDA Insights#
The adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for the quarter reached €89 million, reflecting an 18% year-over-year increase. Despite this growth, it still fell 2% short of the consensus expectation of €91 million. The adjusted EBITDA margin improved to 30.0%, up from 25.9% in the previous year, marking the highest level since early 2023.
Full Year Performance#
For the full year 2025, Dermapharm reported total sales of €1,165 million, which is a 1% decrease from the previous year and slightly below the consensus estimate of €1,183 million. The full-year adjusted EBITDA was €325 million, up 3% year-over-year, with a margin of 27.9%, an improvement from 26.7% in 2024. This figure also fell 1% short of the consensus expectation of €327 million.
Future Outlook#
The increase in margins throughout the year was attributed to portfolio optimization and the reduction of unprofitable parallel import volumes. Dermapharm is set to release its audited results and provide guidance for 2026 on March 31.